doi: 10.1038/sj.ijo.0801083 Summary Keywords Prader-Willi syndrome, obesity, GLP-1 receptor agonist, semaglutide, metabolic surgery Citation Koceva A, Mleku Kozamernik K, Jane A, Herman R, Ferjan S and Jensterle M (2025) Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
Here are some of the key insights that caught my attention
This exceptional characteristic ensures substantial benefits for your overall well-being
Safety and Medical Supervision Peptides should be used under the supervision of a licensed medical professional trained in peptide therapy
No significant human metabolites of streptomycin have been identified, with 50%60% of the drug excreted unchanged in the urine ( Capreomycin, used primarily as a second-line treatment for MDR-TB, has an unclear mechanism of action
Im grateful for them for helping people like me